IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.
PDS Biotech reaffirms the initiation of the VERSATILE-003 Phase 3 clinical trial in Q1 2025 for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
IMUNON's IMNN-001 demonstrated an 11.1-month overall survival improvement in advanced ovarian cancer patients compared to standard of care, marking a significant clinical advancement.
IMUNON has secured FDA alignment on its Chemistry, Manufacturing, and Controls (CMC) strategy for IMNN-001, an immunotherapy targeting advanced ovarian cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.